前列腺癌的DNA甲基化及其临床应用
收稿日期: 2013-12-09
修回日期: 2014-01-14
网络出版日期: 2014-05-25
基金资助
国家自然科学基金项目(编号：30972709, 81061120527, 81241082), 北京医院重大基金项目(编号：BJ-2010-30), 卫生部部属医院临床学科重点项目(编号：01020101), 卫生部行业基金项目(编号：201302008)和科技部十二五支撑计划项目(编号：2012BAI10B01)资助
DNA Methylation of Prostate Cancer and Clinical Application
Received date: 2013-12-09
Revised date: 2014-01-14
Online published: 2014-05-25
目前认为恶性肿瘤的形成是遗传和表观遗传机制共同作用的结果。表观遗传机制包括DNA甲基化、组蛋白修饰和miRNA。DNA异常甲基化(高甲基化和低甲基化)是前列腺癌最具特征的表观遗传改变, 它能够导致基因组不稳定, 调控基因的异常表达, 在前列腺癌的形成和发展中起到重要作用。同时, DNA甲基化作为前列腺癌表观遗传研究的一个热点, 为临床前列腺癌的早期诊断、预后评估及药物治疗提供新的方法和途径。文章根据前列腺癌的DNA高甲基化和低甲基化的最新研究成果阐述了前列腺癌形成的表观遗传学机制, 并且讨论了它们在前列腺癌临床转化方面的最新研究进展。
赵帆, 杨泽 . 前列腺癌的DNA甲基化及其临床应用[J]. 遗传, 2014 , 36(5) : 420 -430 . DOI: 10.3724/SP.J.1005.2014.0420
It is well-known that the interation of both genetic and epigenetic mechanisms results in the formation of malignant tumor. Epigenetic mechanism includes DNA methylation, histone modifications, and miRNA regulation. DNA aberrant methylation (hypermethylation and hypomethylation), which leads to genomic instability and inappropriate gene expression, is the best-characterized alteration in prostate cancer. It plays an important role in the initiation and development of prostate cancer. Meanwhile, DNA methylation, as a hotspot in researches of epigenetics, would provide a new methodology and approach for early clinical diagnosis, prognosis and medication treatment of prostate cancer. According to recent studies on DNA hypermethylation and DNA hypomethylation, this review highlights the potential epigenetic mechanism of prostate cancer and discusses the latest research progress in clinical translation.
Key words： prostate cancer; DNA hypermethylation; DNA hypomethylation
[1] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2095–2128. <\p>
[2] Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev, 2009, 23(7): 781–783. <\p>
[3] Bird AP. CpG-rich islands and the function of DNA methylation. Nature, 1986, 321(6067): 209–213. <\p>
[4] Cooper DN, Krawczak M. Cytosine methylation and the fate of CpG dinucleotides in vertebrate genomes. Hum Genet, 1989, 83(2): 181–188. <\p>
[5] Tian J, Lee SO, Liang L, Luo J, Huang CK, Li L, Niu YJ, Chang C. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2′-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis. J Biol Chem, 2012, 287(47): 39954–39966. <\p>
[6] Daniūnaite K, Berezniakovas A, Jankevi?ius F, Laurinavi?ius A, Lazutka JR, Jarmalaite S. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer. Medicina (Kaunas), 2011, 47(3): 147–153. <\p>
[7] Tang DL, Kryvenko ON, Mitrache N, Do KC, Jankowski M, Chitale DA, Trudeau S, Rundle A, Belinsky SA, Rybicki BA. Methylation of the RARB gene increases prostate cancer risk in black Americans. J Urol, 2013, 190(1): 317–324. <\p>
[8] Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol, 2012, 19(9): 3107–3115. <\p>
[9] Feng QH, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, Jordan CD, Kiviat NB, Vesselle H. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev, 2008, 17(3): 645–654. <\p>
[10] 王长春, 毛伟敏, 凌志强. 维甲酸受体β2和p16INK4α基因甲基化在食管鳞癌患者肿瘤组织和外周血中的表达. 中华肿瘤杂志, 2012, 34(6): 441–445. <\p>
[11] Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, Zahurak M, Goodman SM, Zeiger M, Sidransky D, Umbricht CB, Hoque MO. Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics, 2012, 7(7): 710–719. <\p>
[12] Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res, 2002, 8(2): 464–470. <\p>
[13] Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L, Khabir A, Frikha F, Kallel L, Amouri A, Frikha M, Sellami- Boudawara T, Gargouri A, Mokdad-Gargouri R. Hypermethylation of RARbeta2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma. Tumour Biol, 2010, 31(5): 503–511. <\p>
[14] Piperi C, Themistocleous MS, Papavassiliou GA, Farmaki E, Levidou G, Korkolopoulou P, Adamopoulos C, Papavassiliou AG. High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol Med, 2010, 16(1–2): 1–9. <\p>
[15] Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad- Gargouri R. Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol Ther, 2009, 8(5): 444–451. <\p>
[16] Wolff DW, Xie Y, Deng CS, Gatalica Z, Yang MJ, Wang B, Wang JC, Lin MF, Abel PW, Tu YP. Epigenetic repression of regulator of G-protein signa
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
